BYDUREON™ Receives Marketing Authorization in Europe

BYDUREON™ Receives Marketing Authorization in Europe

BYDUREON showed statistically significant improvements in glycemic control based on reduction of A1C (a measure of average blood sugar over three months) between 1.5 and 1.9 percent after six months.